250 related articles for article (PubMed ID: 27242237)
1. High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana.
Boakye-Appiah JK; Steinmetz AR; Pupulampu P; Ofori-Yirenkyi S; Tetteh I; Frimpong M; Oppong P; Opare-Sem O; Norman BR; Stienstra Y; van der Werf TS; Wansbrough-Jones M; Bonsu F; Obeng-Baah J; Phillips RO
Int J Mycobacteriol; 2016 Jun; 5(2):226-30. PubMed ID: 27242237
[TBL] [Abstract][Full Text] [Related]
2. Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.
Coovadia YM; Mahomed S; Pillay M; Werner L; Mlisana K
PLoS One; 2013; 8(11):e77712. PubMed ID: 24223122
[TBL] [Abstract][Full Text] [Related]
3. Molecular detection of rifampicin resistance by GeneXpert
Rahman H; Khan SU; Khan MA; Qasim M; Jabbar A; Noor S; Khan Z; Khan TA; Hussain M; Muhammad N; Ali N
J Glob Antimicrob Resist; 2017 Jun; 9():118-120. PubMed ID: 28501582
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
[TBL] [Abstract][Full Text] [Related]
5. GeneXpert
Christopher PM; ; Widysanto A
Int J Mycobacteriol; 2019; 8(4):351-358. PubMed ID: 31793505
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of GeneXpert
Habous M; E Elimam MA; Kumar R; L Deesi ZA
Int J Mycobacteriol; 2019; 8(2):132-137. PubMed ID: 31210154
[TBL] [Abstract][Full Text] [Related]
7. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
[TBL] [Abstract][Full Text] [Related]
8. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
[TBL] [Abstract][Full Text] [Related]
9. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.
Polepole P; Kabwe M; Kasonde M; Tembo J; Shibemba A; O'Grady J; Kapata N; Zumla A; Bates M
Int J Mycobacteriol; 2017; 6(1):87-93. PubMed ID: 28317811
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
Mboowa G; Namaganda C; Ssengooba W
BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
[TBL] [Abstract][Full Text] [Related]
11. Implication of Negative GeneXpert Mycobacterium tuberculosis/Rifampicin Results in Suspected Tuberculosis Patients: A Research Study.
Kusumaningrum D; Mertaniasih NM; Soedarsono S; Setiawati R; Pradipta CP
Int J Mycobacteriol; 2024 Apr; 13(2):152-157. PubMed ID: 38916385
[TBL] [Abstract][Full Text] [Related]
12. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
[TBL] [Abstract][Full Text] [Related]
13. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
[TBL] [Abstract][Full Text] [Related]
14. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
[TBL] [Abstract][Full Text] [Related]
15. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.
Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R
PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.
Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H
Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085
[TBL] [Abstract][Full Text] [Related]
17. Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
Wasihun AG; Dejene TA; Hailu GG
PLoS One; 2020; 15(11):e0240361. PubMed ID: 33147218
[TBL] [Abstract][Full Text] [Related]
18. Xpert
Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
[TBL] [Abstract][Full Text] [Related]
19. Frequency of rifampicin-resistant mycobacterium tuberculosis by GeneXpert MTB/RIF assay and its correlates among 2605 probable tuberculosis patients in upper Egypt.
Hassanin ESA; Mohamed Hussein AA; Abdelrheem SS; Dongol E; Mhsb AHA; Zahran AM; Zein M; G Sayed I
Indian J Tuberc; 2023 Jul; 70(3):345-355. PubMed ID: 37562911
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of the InnowaveDX MTB/RIF test for detection of
Deng Y; Ma Z; Su B; Bai G; Pan J; Wang Q; Cai L; Song Y; Shang Y; Ma P; Li J; Zhou Q; Mulati G; Fan D; Li S; Tan Y; Pang Y
Emerg Microbes Infect; 2023 Dec; 12(1):2151382. PubMed ID: 36416478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
